S-1: VivoSim Labs Launches $4M Offering Amidst Going Concern Warning

Sentiment:

Registration Statement 27 March 2026 5:26 PM

VivoSim Labs, a biotech services firm, is conducting a best efforts public offering of up to $4 million in common stock and warrants to fund operations, despite an auditor's 'going concern' warning and significant accumulated losses.

Capital raiseThe company is conducting a 'best efforts' public offering of up to $4,000,000 in common stock or pre-funded warrants, along with common warrants.The offering is split into an Initial Tranche of up to $3,000,000 and a Second Tranche of up to $1,000,000, with the Second Tranche subject to specific closing price and trading volume conditions.Placement Agent Warrants to purchase up to 118,343 shares of common stock will be issued to Joseph Gunnar & Co., LLC as compensation.The company believes that the estimated $3.4 million net proceeds from this offering, combined with existing cash, will fund operations into 2027, but an additional $5.0 million will be needed in 2026 to extend funding through the end of 2027.The company may also sell up to $3.1 million of common stock under an existing Sales Agreement with JonesTrading Institutional Services LLC.

Worse than expectedThe independent registered public accounting firm's report contains an explanatory paragraph stating 'substantial doubt' about the company's ability to continue as a going concern.The company reported a significant accumulated deficit of $350.2 million as of December 31, 2025, and a net loss of $2.7 million for the three months ended December 31, 2025.Current cash on hand is not sufficient to fund operations beyond July 2026, indicating an urgent need for capital.The offering is a 'best efforts' offering with no minimum amount, meaning there is no guarantee that sufficient capital will be raised to address the company's financial needs.New investors will experience immediate and substantial dilution of $0.36 per share, and further dilution is expected from the likely cashless exercise of common warrants, which will not provide additional cash to the company.

Summary

VivoSim Labs, Inc. is undertaking a 'best efforts' public offering to raise up to $4,000,000 through the sale of common stock or pre-funded warrants, along with common warrants.
The offering is structured in two tranches: an initial $3,000,000 and a second $1,000,000 tranche contingent on specific stock price and trading volume conditions.
The company's independent registered public accounting firm has issued an explanatory paragraph indicating 'substantial doubt' about its ability to continue as a going concern.
Current cash on hand is projected to be insufficient to fund operations beyond July 2026, with the offering proceeds (estimated $3.4 million) expected to extend this into 2027, requiring an additional $5.0 million raise in 2026 to fund through the end of 2027.
VivoSim Labs pivoted its business model in April 2025 from a clinical-stage biotech to a pharmaceutical and biotechnology services company, focusing on 3D human tissue models for drug testing.
The company's liver toxicology platform demonstrated 87.5% sensitivity and 100% specificity in identifying liver-toxic drugs, presented at a May 2025 scientific conference.
VivoSim Labs sold its FXR program in March 2025 for $10.0 million upfront, with potential future milestones of up to $50.0 million.
The company continues to advance its Preclinical IBD Program, aiming for an Investigational New Drug (IND) application with the FDA by December 2026.
New investors in this offering will experience immediate and substantial dilution of approximately $0.36 per share.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with cautious optimism. While the company faces severe financial distress, including a going concern warning and substantial accumulated deficit, its strategic pivot to a services model with a 'best-in-class' liver toxicology platform and the sale of its FXR program provide a potential path to future viability. The capital raise is critical for survival.

Positives

The company successfully sold its FXR program for $10.0 million upfront, with potential for up to $50.0 million in future milestones.
The strategic pivot to a services model utilizing 3D human tissue models aligns with the U.S. FDA's April 2025 announcement favoring non-animal testing methods.
The liver toxicology platform demonstrated strong predictive power with 87.5% sensitivity and 100% specificity for challenging liver toxicity cases, indicating a potentially valuable service offering.
The Preclinical IBD Program is advancing, with a goal to have a product candidate ready for an IND with the FDA by December 2026.

Negatives

The company has incurred substantial losses since inception, with an accumulated deficit of $350.2 million as of December 31, 2025, and a net loss of $2.7 million for the three months ended December 31, 2025.
Independent auditors have expressed 'substantial doubt' about the company's ability to continue as a going concern.
Current cash on hand is insufficient to fund operations beyond July 2026, making the capital raise critical for short-term survival.
The offering is a 'best efforts' public offering with no minimum amount, creating uncertainty regarding the actual capital that will be raised.
New investors will face immediate and substantial dilution of approximately $0.36 per share.
Common warrants are likely to be exercised on a cashless basis, which will not provide additional cash proceeds to the company but will cause further dilution.
There is no established public trading market for the common warrants or pre-funded warrants, limiting their liquidity.
The company is subject to a Nasdaq Mandatory Panel Monitor until April 30, 2026, due to prior non-compliance with listing requirements, with a risk of delisting if further non-compliance occurs.
Ongoing litigation with H.C. Wainwright & Co., LLC, including a counterclaim by the company, poses financial and operational risks.

Risks

Inability to raise sufficient capital in this offering or future offerings to support operations, potentially leading to reduced expenses, delayed R&D, or cessation of operations.
Failure to satisfy the conditions for closing the Second Tranche of the offering, which would reduce the total proceeds received.
Substantial dilution for investors due to the issuance of shares and the likely cashless exercise of common warrants.
Lack of a public trading market for common warrants and pre-funded warrants, limiting their liquidity and market value.
Risk of failing to maintain the listing of common stock on the Nasdaq Capital Market, which could harm liquidity and ability to raise capital.
Management's broad discretion in using the net proceeds from the offering, which may not ultimately increase investment value.
Future sales of additional equity or convertible debt securities could result in further dilution and cause the stock price to fall.
Risks associated with strategic transactions, including difficulties in integration, financing, or realizing expected benefits from acquisitions or divestitures.
Adverse effects from changes to tax laws, such as the One Big Beautiful Bill Act (OBBA), on the company or holders of common stock.
Potential adverse effects on business, operating results, and financial condition from ongoing or future claims, litigation, government investigations, and other proceedings, including the H.C. Wainwright lawsuit.

Future Outlook

The company anticipates that the net proceeds from this offering, estimated at $3.4 million, combined with existing cash, will fund operations into 2027. To meet capital needs through the end of 2027, an additional $5.0 million in net proceeds would need to be raised through the sale of securities or other means throughout 2026. The company aims to advance its Preclinical IBD Program to an Investigational New Drug (IND) application with the FDA by December 2026 and plans to actively market its liver toxicology and intestinal side effect prediction services, including partnering with contract research organizations (CROs).

Management Comments

The company's name change to VivoSim Labs, Inc. reflects its new business model, which leverages existing assets, intestinal and liver toxicology models, expertise, and its IP portfolio for 3D bioprinting.
Management believes the liver toxicology platform's 87.5% sensitivity and 100% specificity is 'worlds best' and offers a 'best-in-class predictive power'.
The company expects accelerated adoption of human tissue models following the FDA's April 2025 announcement to refine animal testing requirements in favor of non-animal methods.
The company's proprietary technologies are used to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease, enabling complex multicellular disease models for drug study and development.

Industry Context

StockSavvy.ai notes VivoSim Labs' strategic pivot to a services-based model, focusing on 3D human tissue models for drug testing, aligns with a significant industry trend driven by regulatory changes. The FDA's April 2025 announcement favoring non-animal testing methods creates a favorable environment for companies offering New Approach Methodologies (NAMs). VivoSim's reported 'best-in-class' liver toxicology platform, with high sensitivity and specificity, positions it to capitalize on the pharmaceutical industry's need to reduce high drug development costs and failure rates associated with traditional animal testing and unexpected toxicities. This move could allow VivoSim to become a key player in the preclinical drug development services market, competing with established CROs and specialized biotech service providers.

Comparison to Industry Standards

The company claims its liver toxicology platform has 'best-in-class predictive power' with 87.5% sensitivity and 100% specificity for challenging liver toxicity cases, which it states is a 'worlds best'. This performance is presented as superior to existing methods in the industry for predicting drug-induced liver injury.
The company highlights that less than 10% of drug candidates entering clinical trials are approved, with liver toxicity and intestinal intolerability being major causes of failure. VivoSim's services aim to significantly improve upon this industry-wide challenge by providing more predictive preclinical models.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Choice of Forum	Bylaws specify the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain corporate actions, potentially limiting stockholders' ability to bring claims in other jurisdictions.	NA	May limit stockholders' flexibility in legal proceedings and could increase litigation costs for non-Delaware residents, potentially discouraging certain lawsuits against the company or its management.
Board Structure	The Certificate of Incorporation establishes a classified board of directors divided into three classes with staggered three-year terms, and directors can only be removed for cause.	NA	Designed to discourage hostile takeovers by making it more difficult for stockholders to replace a majority of directors, promoting management continuity but potentially limiting stockholder influence.
Stockholder Meetings	Bylaws state that special meetings of stockholders can only be called by the chairperson of the Board, CEO, president, or a majority of authorized directors, not by stockholders.	NA	May delay stockholders' ability to force consideration of proposals or take action, including director removal, without management's initiation.
Stockholder Action by Written Consent	The right of stockholders to act by written consent without a meeting is eliminated unless approved in advance by a Board resolution.	NA	Prevents a majority stockholder from amending bylaws or removing directors without a formal meeting and Board approval, further centralizing control with the Board.
Advance Notice Requirements	Bylaws establish advance notice procedures for stockholder proposals and director nominations.	NA	May preclude stockholders from bringing matters or nominations before annual meetings if proper procedures are not followed, potentially deterring proxy solicitations or attempts to gain control.
Cumulative Voting	The Certificate of Incorporation does not permit stockholders to cumulate their votes in the election of directors.	NA	Allows holders of a majority of common stock to elect all directors, potentially limiting minority stockholder representation on the board.
Preferred Stock Issuance	The Board is authorized to issue up to 25,000,000 shares of undesignated preferred stock with voting or other rights/preferences determined by the Board, without further stockholder action.	NA	Provides flexibility for corporate purposes but could be used to delay, defer, or prevent a change in control, potentially affecting the market price and voting rights of common stockholders.
Delaware Law Applicability	The company is subject to Section 203 of the DGCL, which prohibits interested stockholders from engaging in business combinations for three years unless certain conditions are met.	NA	Has an anti-takeover effect, discouraging transactions not approved in advance by the Board and potentially limiting opportunities for stockholders to sell shares at higher prices.

Legal Proceedings

On August 27, 2024, H.C. Wainwright & Co., LLC filed a complaint against the company in New York State, alleging breach of a tail financing provision from a May 2023 engagement agreement, seeking compensatory and consequential damages and attorneys' fees.
On September 2, 2025, the company filed an amended answer and counterclaimed against H.C. Wainwright, alleging rescission, fraudulent inducement, and breach of contract, seeking damages, interest, costs, and attorneys' fees.
The company is vigorously defending against H.C. Wainwright's claims and pursuing its counterclaims, but there is no guarantee of success, and the litigation could be time-consuming and expensive.

Related Party Transactions

None explicitly disclosed as new or significant in the filing beyond standard compensation for employees, officers, and directors, and reimbursement for expenses, or other employee benefits, in amounts not exceeding $120,000.

Stakeholder Impact

Shareholders: Will experience significant dilution from the offering and potential cashless warrant exercises. Existing shareholders face risk of further value erosion due to the company's financial distress and potential delisting. New investors face immediate dilution.
Employees: Continued employment and potential for growth are contingent on the company successfully raising capital and executing its new business strategy.
Customers (Pharmaceutical/Biotech Companies): Potential benefit from access to VivoSim's advanced 3D human tissue models for drug testing, which could reduce R&D costs and risks, aligning with new FDA guidelines.
Creditors: Face increased risk due to the company's 'going concern' warning and accumulated deficit, although a successful capital raise could mitigate some of this risk.
Placement Agent (Joseph Gunnar & Co., LLC): Will receive cash fees (7.5% of gross proceeds) and Placement Agent Warrants (5% of shares/pre-funded warrants sold) for its role in the offering.

Next Steps

Complete the 'best efforts' public offering to raise necessary capital.
Work towards satisfying the conditions for the Second Tranche closing of the offering.
Advance the Preclinical IBD Program to have a product candidate ready for an Investigational New Drug (IND) application with the FDA by December 2026.
Actively market liver toxicology predictive screening and research services to pharmaceutical and biotech companies.
Form partnerships with contract research organizations (CROs) to expand client portfolio.
Potentially raise an additional $5.0 million in 2026 to meet capital needs through the end of 2027.
Continue to defend against the H.C. Wainwright & Co., LLC lawsuit and pursue counterclaims.
Maintain compliance with Nasdaq listing requirements to avoid delisting.

Key Dates

Date	Description
April 10, 2025	U.S. Food and Drug Administration (FDA) announced refinement of animal testing requirements in favor of non-animal New Approach Methodologies (NAM) models.
March 2025	Company sold its FXR program for $10.0 million upfront, with $1.0 million held in escrow for 15 months, and potential future milestones up to $50.0 million.
April 24, 2025	Corporate name changed to VivoSim Labs, Inc. from Organovo Holdings, Inc.; common stock began trading on Nasdaq Capital Market under symbol VIVS.
May 2025	Company presented findings at the Digestive Disease Week scientific conference, showing its liver toxicology platform had 87.5% predictive power (sensitivity) and 100% specificity.
June 5, 2025	Independent registered public accounting firm's report on financial statements for fiscal year ended March 31, 2025, contained explanatory language about substantial doubt regarding the company's ability to continue as a going concern.
August 27, 2024	H.C. Wainwright & Co., LLC filed a complaint against the company alleging breach of a tail financing provision.
September 2, 2025	Company filed an amended answer and counterclaimed against H.C. Wainwright & Co., LLC for rescission, fraudulent inducement, and breach of contract.
December 31, 2025	Company reported net losses of $2.7 million for the three months ended, and an accumulated deficit of $350.2 million. Net tangible book value was approximately $3.2 million, or $1.23 per share.
March 26, 2026	Last reported sale price of common stock on the Nasdaq Capital Market was $1.69 per share.
March 27, 2026	Filing date of the S-1 Registration Statement.
April 30, 2026	Scheduled termination date of the public offering, unless closed earlier or terminated by the company.
July 2026	Current cash on hand is not sufficient to fund operations beyond this date.
August 17, 2026	Expiration date of the Placement Agent's Participation Right in future financings.
December 2026	Goal to have a product candidate from the Preclinical IBD Program ready for an Investigational New Drug (IND) application with the FDA.
End of 2027	Projected period through which capital needs would be met if $3.4 million from this offering and an additional $5.0 million are raised in 2026.

Recommendation

sell

A seasoned investor would likely recommend 'Sell' due to the severe financial distress indicated by the 'going concern' warning from independent auditors, the substantial accumulated deficit, and ongoing net losses. While the strategic pivot to a services model and promising platform data offer long-term potential, the immediate need for capital, the 'best efforts' nature of the offering, and the significant dilution for new investors present considerable near-term risks. The uncertainty surrounding the Second Tranche closing and the likelihood of cashless warrant exercises further exacerbate dilution without providing additional cash. The company's ability to execute its business plan and achieve profitability remains highly speculative given its current financial state.

Keywords

Biotechnology, Pharmaceutical Services, 3D Tissue Models, Liver Toxicology, IBD, Drug Discovery, SEC Filing, S-1, Public Offering, Warrants, Common Stock, Nasdaq, VIVS, Capital Raise, Going Concern

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.